Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes

Go back to Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes
(NASDAQ: ZEAL) Delayed: 17.59 --0 (-0%)
Previous Close $17.59    52 Week High $ 
Open $1.35    52 Week Low $ 
Day High $17.59    P/E N/A 
Day Low $17.59    EPS $ 
Volume 15,962